Overview

* ProQR Q3 revenue missed analyst expectations

* Company reported a net loss of €11 mln for Q3 2025

* ProQR received CTA authorization for Phase 1 trial of AX-0810

Outlook

* ProQR expects initial safety data for AX-0810 by end of 2025

* Target engagement data for AX-0810 expected in H1 2026

Result Drivers

* CASH POSITION - Strong cash position provides runway into mid-2027, supporting pipeline and partnership activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss EUR 2.88 EUR 4.36

Revenue mln mln (7

Analysts

)

Q3 EPS -EUR

0.10

Q3 Net -EUR

Income 11.01

mln

Q3 Basic -EUR

EPS 0.10

Q3 -EUR

Operatin 11.28

g Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for ProQR Therapeutics NV ( PRQR ) is $8.50, about 72% above its November 5 closing price of $2.38

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)